South Korea’s government is attempting to successfully execute a belated but ambitious COVID-19 vaccination strategy. The government will attempt to achieve the full rollout of expanded public funding (and reimbursement rates) that predated the COVID-19 crisis.
FrontierView’s most recent Quarterly Healthcare Market Review explores several key healthcare market developments:
- South Korea’s late push to its vaccination plan will delay achieving herd immunity
- The Government’s ambitious public healthcare expansion has led to significant opposition
- Reduced health expenditures have left the NHIS in stronger fiscal shape
According to our latest review, South Korea remains a solid bet for demand recovery for global healthcare companies. However, the pricing and reimbursement environment will be a challenge for pharmaceutical and medical device companies since The Moon administration has an ambitious healthcare agenda, committed to expanding access and improving out-of-pocket (OOP) pressures.
See what is happening beyond our to market trends, stay ahead of reimbursement environments and enhance your performance in Asia’s must-win markets and download our free mobile app, available on iOS and Android. To receive access to our full research, data, and insights on your critical markets, start your free trial of FrontierView today.